The antidepressant effects of psychedelics may be overestimated in studies with pre-post single-arm, non-active-drugs-as placebo, and waitlist-control designs. Restricted sample size, difficulty with establishing blinding for participants, and over expectancy limit the estimation of the antidepressant effect of psychedelic-assisted therapy.

We explore psilocybin as a potential treatment option for PTSD by examining the neurobiology of PTSD as well as psilocybin’s mechanism of action. Based on both pharmacodynamic and psychoanalytic principles, psilocybin may be an underexplored treatment option for patients with PTSD, though further research is required.

Results suggest that most meditators found psychedelic use to have a positive influence on their meditation practice, with: 1) regularity of psychedelic use, 2) the setting of intentions for psychedelic use, 3) having an agreeable personality, and 4) reported use of N,N-DMT being the most likely predictors of perceiving psychedelic use as beneficial.

At 1-month follow-up, the meditators who received DMT and harmine rated their experience as significantly more personally meaningful, spiritually significant, and well-being-enhancing than the meditators who received placebo.

The intervention (for PTSD) is composite, and its outcomes assumed to result from MDMA facilitating the effects of psychotherapy. In this Viewpoint, we argue that the psychotherapy component plays a critical role in assessing the validity of the trials.

I believe this will be one of the next conditions, if not the next condition, to be considered for the designation of innovative treatment in future psilocybin regulation in the United States

This group of US pharmacists have started a website where they advertise: "Receive an instant, evidence-based report on psilocybin mushroom interactions with your medications and health conditions."

The results indicate that Idealism specifically, not non-physicalist beliefs generally, mediate a link between the use of psychedelics and wellbeing. Future research is required to establish whether the link is causal, and to understand what the Idealism factor means.

This study indicates the positive effects of microdosing psychedelics on ADHD symptoms and emotion regulation in adults with severe ADHD symptoms while lacking evidence for effects on empathy.

These data suggest that the IPPS is predictive of relevant acute features of the psychedelic experience in a broad range of contexts. We hope that this brief 9-item scale will be widely adopted for improved knowledge of psychedelic preparedness in controlled settings and beyond.

Patients showed a significant decrease in MADRS scores, and the greatest predictor of antidepressant outcome was relaxation during the PAT session.

The spot is called Kokopelli, named after a North American fertility deity, and it’s low-key legendary: when it opened in 1994, it was one of the first “smart shops” to sell psilocybin mushrooms over the counter, and it remains a tripper sanctuary.

These findings demonstrate the involvement of the ANS in psychedelic-induced peak experiences and may pave the way to the development of biofeedback-based tools to enhance psychedelic therapy.

Psilocybin leads to a better overall outcome in the treatment of moderate to severe major depressive disorder (MDD) than the selective serotonin reuptake inhibitor (SSRI) escitalopram, results of the first long-term comparison of the two treatments suggest.

An in-training PaT experience supports personal comfort, self-assuredness, and confidence supporting others in non-ordinary states of consciousness, with contemporary researchers/experts highlighting the specific challenges among therapists who lack lived experience.

Results suggest that most meditators found psychedelic use to have a positive influence on their meditation practice, with: 1) regularity of psychedelic use, 2) the setting of intentions for psychedelic use, 3) having an agreeable personality, and 4) reported use of N,N-DMT being the most likely predictors of perceiving psychedelic use as beneficial. Longitudinal designs and randomized trials manipulating psychedelic use are needed to establish causality.

This perspective on experiential training delves into the potential benefits and counterarguments related to integrating firsthand experience of psychedelic-assisted therapy (PaT) to enhance the competency of trainees.

Percentage of patients who are eligible are 24% (lower-bound), 56% (mid-range), and 62% (upperbound). Variance was largely influenced by the removal of alcohol and substance use disorders as exclusion criteria.

Compared with manualized nondirective psychological support, the other three psychological approaches did not differ significantly. The improvement of depressive symptoms was not associated with the psychological protocols in adult patients receiving psilocybin-assisted therapy.

Reports of serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric attention in classic psychedelic research were rare. In this systematic review and meta-analysis of 3504 participants from 114 studies, SAEs were reported for no healthy participants and approximately 4% of participants with preexisting neuropsychiatric disorders; however, for most studies, there was concern for underdetection or incomplete AE reporting.